Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01189253 · ClinicalTrials.gov registry record · Phase 2
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
A Phase 2 study, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
- Terminated
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
NCT01189253: Clinical Trial Phase 2 study, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
NCT01189253 is a Phase 2 study that was terminated before completion, run by European Organisation for Research and Treatment of Cancer - EORTC. The registered enrollment target is 133 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01189253, a Phase 2 study, was terminated before completion, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride and trabectedin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether trabectedin is more effective than doxorubicin hydrochloride in treating patients with advanced or metastatic soft tissue sarcoma. PURPOSE: This randomized phase II/III trial is studying the safety of trabectedin compared with doxorubicin hydrochloride and to see how well they work in treating patients with advanced or metastatic soft tissue sarcoma.
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE quality-of-life assessment
- DRUG doxorubicin hydrochloride
- DRUG trabectedin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2011-05 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Why NCT01189253 stopped before completion
NCT01189253 is an interventional study that assigns participants to a tested intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01189253 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01189253 about?
NCT01189253 is a clinical study titled "Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma". RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride and trabectedin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether trabectedin is more effective than doxorubicin hydrochloride ...
What is the current status of trial NCT01189253?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2011-05. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01189253?
The interventions under investigation include: laboratory biomarker analysis (OTHER), quality-of-life assessment (PROCEDURE), doxorubicin hydrochloride (DRUG), trabectedin (DRUG).
Who is sponsoring clinical trial NCT01189253?
This trial is sponsored by European Organisation for Research and Treatment of Cancer - EORTC, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01189253's enrollment target sits among peer trials
133 538th of 2000 higher than 1,462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276870 · 133 participants · Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
- NCT04671771 · 133 participants · NA
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- NCT05610085 · 133 participants · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- NCT06206486 · 133 participants
The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia